With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
IDXX trades against a final fair-value range of $231.99-$439.23, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
A prolonged macroeconomic downturn could reduce discretionary veterinary clinic traffic, stalling instrument placements and consumable volume growth, while a high starting valuation multiple compresses.
Market recalibrates the extreme 39x trailing P/E multiple down to the model's 25x terminal multiple constraint.
A prolonged recession reduces discretionary veterinary clinic traffic, stalling instrument placements and recurring consumable volumes.
Competition forces aggressive pricing, causing operating margins to fall below the historically stable 30-31.6% range.
| Line item | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|---|
| Revenue | $3.22B | $3.37B+4.7% | $3.66B+8.6% | $3.90B+6.6% | $4.30B+10.3% | +7.6% |
| Gross profit | $1.89B | $2.00B | $2.19B | $2.38B | $2.66B | +8.9% |
| Operating income | $932.0M | $898.8M | $1.10B | $1.13B | $1.36B | +9.9% |
| Net income | $744.8M | $679.1M-8.8% | $845.0M+24.4% | $887.9M+5.1% | $1.06B+19.4% | +9.2% |
| EPS (diluted) | — | $8.03 | $10.06 | $10.67 | $13.08 | +13.0% |
| EBITDA | $1.04B | $1.01B | $1.22B | $1.27B | $1.51B | +9.8% |
| R&D | $161.0M | $254.8M | $191.0M | $219.8M | $251.2M | +11.8% |
| SG&A | $796.4M | $850.8M | $901.9M | $1.03B | $1.05B | +7.1% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Market-implied growth expectations failing to meet the 15.29% hurdle. | Monitor | Deterioration versus the report thesis |
| Terminal multiple compression accelerating toward the 25x model anchor. | Monitor | Deterioration versus the report thesis |
